Full Report

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

Industry — Understanding the Playing Field

Supreme PLC sits inside a portfolio of UK consumer-packaged-goods sub-industries knit together by one channel: the UK's grocers, discounters and convenience network. The arena is a manufactured-and-distributed FMCG platform whose three sub-industries are UK vaping (profit engine, most regulated), UK soft drinks and sports nutrition ("Drinks & Wellness", the growth lever), and UK batteries and household lighting (mature, cash-generative, declining). The unifying business is shelf space: get a branded or licensed product onto a UK retailer's planogram, ship it from a Manchester warehouse the same week, and earn manufacturer-plus-distributor margin.

The framing that matters: this is not a tobacco, soft-drinks, or wholesale business — it is a vertically integrated branded FMCG manufacturer-distributor whose moat is the relationship with UK retail buyers, not any single product. Categories rotate; the shelf relationship is the durable asset.

1. Industry in One Page

Sources: Supreme AR2025, H1 FY2026 results, Expert Market Research (UK soft drinks $26.6B in 2025), GOV.UK (vape duty), management commentary on UK vape market value of $4bn+.

The map. Branded consumer goods (someone else's name on the box) and licensed goods (Supreme manufactures under Energizer, JCB, Black+Decker contracts) flow through a Trafford Park hub to ~3,300 trade accounts that operate ~55,000 retail outlets and ~120 export customers. Money is made where Supreme can either own or license a brand customers ask for, manufacture it cheaper than imports, and turn the warehouse fast enough to keep working capital inside its $54m revolving facility. Cycles are driven not by a single end-market but by regulatory pulses (the 1 June 2025 disposable vape ban, the 1 October 2026 vape excise duty) and retailer destocking (visible in batteries and lighting in FY25-H1 FY26). Margins are highest in vaping (transition risk), structurally rising in Drinks & Wellness (acquisition driven), and lowest but most reliable in Electricals.

2. How This Industry Makes Money

The revenue model is wholesale unit shipment — one pallet of e-liquid, batteries, or canned drinks ships from Manchester at a price negotiated with the retailer's category buyer. The pricing unit is per case (or per kg / per ml for liquids); the customer is the retailer, not the consumer. Beneath that simple statement, three economic levers determine where profit pools form.

Where the lever sits. A pure distributor earns 5-10% gross. A pure manufacturer earns 25-35% gross but carries factory cost. Supreme's structural advantage is vertical integration — manufacturing in-house in vaping, e-liquid, sports-nutrition powders and (since 2024) soft drinks, and licensing/distributing branded electricals — so the group captures both manufacturing and distribution margin on the SKUs it owns or licences. That is why Supreme's blended gross margin runs 28-32% versus a pure-distributor like Bunzl at single digits.

Capital intensity is moderate. Capex ran ~$4-7m a year on a $260m+ revenue base before the 2024-25 manufacturing build-out. Working capital — inventory and trade receivables against retailer payment terms — is the bigger investor concern. Supreme's working capital cycle widened in H1 FY26 by ~$15m partly because vaping shipments shifted from air-freight to sea-freight, lengthening stock-in-transit by weeks. Working-capital intensity, not capex, is the real capital signature of this business.

Bargaining power. The retailer holds the gun. UK grocery is dominated by four supermarkets (Tesco, Sainsbury's, Asda, Morrisons) plus the variety discounters (B&M, Home Bargains, Poundland, The Range); together they decide whether a SKU exists nationally. Supplier defenses are: (i) own a brand the retailer's customers ask for by name (Typhoo, SCI-MX, SlimFast); (ii) licence a global brand the retailer can't source elsewhere at scale (Energizer batteries, JCB lighting); (iii) be the only supplier with the manufacturing footprint to deliver UK-made stock at speed (e-liquid, canned soft drinks). All three are levers Supreme operates.

3. Demand, Supply, and the Cycle

Each of Supreme's three sub-industries cycles differently, and that is part of the investment case — but it is also where the risk concentrates.

The disposable-vape playbook is a useful case study of how this industry cycles. When the UK announced a ban on single-use vapes (effective 1 June 2025), the entire ~$900m+ disposable category started to disappear over 18 months. Supreme's disposable revenue went from $89m (FY24) to $70m (FY25) and management guided to $5.9m in H1 FY26 with the residual going to zero. The industry response was binary: scale players (Supreme, IMB-owned Blu/Logic) accelerated investment in pod and rechargeable formats; sub-scale importers and brand-stretchers exited or sold. The cycle hits revenue first, margin second — disposables ran ~20% gross; pods compress that for the first 12-18 months as retailers and consumers reset.

Soft drinks moves on a different clock. The 2018 Soft Drinks Industry Levy (the "sugar tax") was a one-time reformulation event the industry largely absorbed via low/no-sugar variants; it now sits in the price stack. Today's drivers are energy-drinks volume growth (Carabao, Monster, Red Bull) and away-from-home recovery; supply constraints are factory canning capacity and PET prices. Supreme entered this cycle late — Clearly Drinks 2024, Carabao licence 2026 — meaning the curve is ahead of it, not behind.

Sports nutrition cycles on commodity inputs. Whey protein concentrate, the principal raw material for most powders, spiked roughly 2.5x between 2021 and 2023, compressing margins industry-wide; that has since normalised. The current driver is the GLP-1 weight-loss adjacency — branded calorie-control products (SlimFast, meal replacements) sit alongside the GLP-1 prescription wave as complementary, not competing, products.

Batteries and lighting are mature. UK alkaline battery volumes are flat to declining; lighting is in structural deflation as LED bulbs last longer and unit prices fall. Both segments have been cash-generative for Supreme but were under pressure in H1 FY26 from Panasonic's UK exit (battery destocking) and ongoing lighting price deflation.

4. Competitive Structure

The competitive structure differs by category and that is the central thing to understand: Supreme does not have one peer set, it has three, and on its blended financials it lives in the gap between them.

Market caps as of late April / early May 2026, converted to USD at prevailing rates. SUP shown for reference; competitive analysis lives in the Competition tab.

Vaping in the UK is moderately concentrated at the top (Imperial Brands' Blu and Logic, BAT's Vuse, JTI's Logic, plus Chinese brands ElfBar and Lost Mary that Supreme distributes) and highly fragmented at the long tail, where hundreds of importers compete in convenience channels. The 1 June 2025 disposables ban is consolidating the long tail rapidly — sub-scale importers without TPD-compliant pod portfolios are exiting, and the forthcoming October 2026 vape duty will accelerate that consolidation. Supreme management explicitly flags this as an M&A opportunity.

UK soft drinks is bifurcated: two global majors (Coca-Cola HBC and Britvic / Suntory) plus a tier of UK challengers (AG Barr, Nichols/Vimto, Fevertree, Princes-owned Robinson's). Energy drinks are the fastest-growing sub-segment, with Carabao, Monster and Red Bull leading. Supreme's entry strategy is to distribute Carabao (April 2026 licence) and produce in-house at Clearly Drinks rather than compete head-on in cola or orange.

UK sports nutrition is fragmented across direct-to-consumer (Myprotein, Bulk, Innermost), retail brands (Holland & Barrett's own range, SCI-MX, USN, MaxiNutrition), and listed pure-plays (Applied Nutrition, Science in Sport). Wellness and weight-management — where SlimFast sits — overlap with mainstream FMCG and have benefited from the GLP-1 halo.

Batteries and lighting are oligopolies at the brand level (Energizer, Duracell, Panasonic on batteries; multinational LED brands plus retailer private label on lighting) but heavily licensed and OEM-sourced; Supreme is the licensee for Energizer batteries and JCB / Black+Decker lighting in the UK, which gives it unusual scale relative to its market cap.

The structural takeaway: Supreme's categories are individually too small or too regulated for global FMCG focus, and too channel-complex for any single UK challenger to dominate. The defensible position is being the largest UK player who can manufacture, brand-license, and distribute simultaneously into the four big grocers and the variety-discount channel.

5. Regulation, Technology, and Rules of the Game

Regulation is the single biggest external driver of revenue and margin in Supreme's most profitable segment, and the timeline is unusually visible.

Sources: GOV.UK (Vaping Products Duty notice, 26-Nov-2025; Tobacco and Vapes Bill 2024); Reuters (22-Apr-2026 royal assent); Supreme AR2025; HMRC duty stamp guidance.

Read this timeline as a P&L bridge. The disposable ban already happened (it cut $21m from FY25 vape revenue). The 1 October 2026 duty adds ~60¢ to a typical 2ml replacement pod and $3.00 to a 10ml e-liquid bottle; the variance is whether it passes through to retail price or compresses trade margin if retailers refuse. The Tobacco and Vapes Bill grants ministers power to regulate flavours and packaging via secondary legislation — a pending, dated risk. The generation tobacco ban is a multi-decade tailwind for vaping as a cessation tool, contingent on vaping not being regulated into commercial unviability first.

Other rules to know. Beyond vape: WEEE (electricals waste) and packaging EPR (extended producer responsibility) levies bear on batteries and lighting. The Soft Drinks Industry Levy is already in the price stack but periodic revisions are possible. Sports nutrition is governed by the Foods Supplements Regulations and labelling rules — light-touch versus vape but tightening on health claims. None of these are decisive individually; the vape regulatory stack is.

Technology. The relevant shifts are: (i) the pod-and-rechargeable transition in vaping, which is execution-led rather than IP-led; (ii) GLP-1 weight-loss drugs reshaping the wellness category (creating both a halo and an existential question for some legacy brands); (iii) automation in canning and powder lines, where Supreme is investing post-Clearly Drinks and Typhoo; (iv) e-commerce growing as a parallel channel, especially for sports nutrition (Myprotein D2C model). None of these are venture-capital "platform" technologies — they are operating capabilities that define cost and speed.

6. The Metrics Professionals Watch

The metrics that explain value creation in this industry are not generic FMCG ratios — they are concentrated on category mix, working-capital velocity, and regulatory exposure.

Indicative SUP values: vape mix from FY25 group revenue ($167m of $299m); EBITDA margin 17.5% FY25; gross margin 31.9% FY25; trade accounts 3,300; H1 FY26 acquisitions completed: Clearly Drinks, Typhoo, 1001, SlimFast (4 deals across past 18 months); disposable revenue H1 FY26 $5.9m guided to ~$0.

7. Where Supreme PLC Fits

Supreme's correct industry label is "vertically integrated branded FMCG manufacturer-distributor" — a hybrid that does not sit cleanly in a single sector taxonomy (Morningstar files it under Conglomerates / Industrials; LSE indexes it under Consumer Staples; Motley Fool tags it Distributors). This positioning is not a packaging accident — it is the strategy.

8. What to Watch First

A short investor checklist for the next 12 months — each signal is observable in filings, RNS, retailer trade-press, or HMRC data.

Know the Business — Supreme PLC

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bottom line. Supreme is a UK vertically-integrated branded FMCG manufacturer-distributor whose moat is the relationship with UK retail buyers — vape, drinks, sports nutrition, batteries and lighting all flow through one Manchester warehouse to the same 3,000+ trade accounts. Earnings are concentrated in vaping (~56% of revenue, ~36% gross margin), and the market prices the whole company at a regulated-tobacco-adjacent multiple (5x EV/EBITDA, 8x P/E) while management spends $65m+ to halve that vape mix. The market is paying for the vape regulatory mix and giving the platform rotation for free; whether that read is right depends on what vape gross margin does after the 1 October 2026 duty.

1. How This Business Actually Works

Supreme makes money by getting branded or licensed products onto a UK retailer's planogram, shipping them from one Trafford Park hub, and earning manufacturer-plus-distributor margin on each pallet. Three things drive incremental profit: (1) which category the next pallet goes into — vape contributes >2x the gross-margin density of electricals, (2) whether Supreme owns or just distributes the brand on it — own-brand and in-house manufactured SKUs earn 1.5-2x the gross margin of factored OEM, and (3) how fast the inventory turns — at 70 inventory days and 61-day cash-conversion-cycle, working capital, not capex, is the binding constraint.

The vertical-integration premium. A pure UK FMCG distributor (Bunzl, Kitwave) earns single-digit gross margin. A pure manufacturer (Premier Foods) earns ~38% on a much heavier asset base. Supreme runs a 32% blended gross margin on $40m of net PP&E because it manufactures in-house in vaping (e-liquid, devices), sports nutrition (powders, gels), and now drinks (Clearly Drinks, Typhoo) — and licenses globally-recognised brands (Energizer, JCB) the retailer can't source elsewhere at scale. The same Manchester warehouse, sales team and ABL facility carry all of it.

Working capital is the choke point, not capex. Capex ran $4-7m on a $260m revenue base for years. The real capital signature is the $47m of inventory and $55m of receivables on the FY25 balance sheet, financed by a $54m HSBC asset-based lending facility ($46m undrawn at H1 FY26). Working capital widened by $14.8m in H1 FY26 — partly the seasonal pre-Christmas inventory build, partly a deliberate switch from air-freight to sea-freight on vape lines (lengthening stock-in-transit by weeks for the sake of long-term margin). When Supreme grows organically, cash unwinds; when it shifts mix or acquires, working capital absorbs cash before the synergies show.

Bargaining power runs against Supreme on the customer side and with it on the supplier side. One UK retailer (almost certainly B&M, Home Bargains or a comparable variety discounter) accounted for $28.7m of H1 FY26 revenue (16% of group); two customers were >10% in H1 FY25. That is the price of being a value-led FMCG supplier into a concentrated UK retail market. The defenses are owning the brand the consumer asks for (Typhoo, SCI-MX, SlimFast), holding a long-running licence the retailer cannot replicate (Energizer to 2030, JCB renewed), and being the only UK supplier with the vertical footprint to ship UK-made stock at speed.

2. The Playing Field

Latest reported FY for each name; market caps as of late April / early May 2026. SUP reflects FY25 (Mar-2025) and 162.5p close.

What the peer set reveals. Supreme's margin profile sits between Premier Foods (mature multi-cat branded) and the soft-drinks/wellness pure-plays — but its multiple sits below all of them and only slightly above HFG, a low-margin food packer. The market is paying for the regulated-vape mix and the working-capital fragility, not for the platform optionality. The two structural takeaways:

• No peer competes across all three of Supreme's categories. NICL is the soft-drinks comparable, APN the sports-nutrition comparable, IMB the vape comparable, PFD the closest multi-cat branded food template. None has Supreme's exact mix, which is exactly why no single multiple fits.
• "Good" in this peer set means high margin density on low capex. Applied Nutrition (27% EBITDA margin, 0.9% capex/rev, 34% ROIC) is the best-in-class economic model — and trades at 10.5x EV/EBITDA on 24% growth. Supreme's underlying ROIC (30%) and capex/rev (1.4%) are already in that neighbourhood; the mix is what separates them. APN does not yet have to bridge a regulated-revenue runoff; Supreme does.

The honest read: Supreme is an APN-quality return engine bolted onto an IMB-style regulated vape revenue stream, distributed through a PFD-style multi-category platform. The market prices it as the IMB part — the rest is conditional optionality on the rotation working.

3. Is This Business Cyclical?

Supreme is not economically cyclical — it is regulatory cyclical. GDP-recession beta is low because the value end of UK FMCG benefits from down-trading; that is observable in 8 years of EBITDA, which has compounded ~22% even through 2020-22. The cycle that matters is the regulated-vape pulse, and it is on a published timetable.

The disposable ban was the first regulatory shock; it is essentially absorbed. The $3.00-per-10ml vape duty (1 Oct 2026) is the second and the harder one — it adds $0.60 of duty to a 2ml replacement pod and $3.00 to a 10ml e-liquid bottle. Whether this compresses Supreme's margin or passes through to retail price depends on the elasticity of the consumer and the willingness of B&M / Home Bargains to take the price increase. The pod-format gross margin compression in H1 FY26 (33% → 31%) is the early read; if it holds at that level post-duty, the bear case is contained. If it slides toward 25%, the rotation thesis is in trouble.

4. The Metrics That Actually Matter

Latest values: vape mix and gross margin from H1 FY26 (Vaping $103m of $178m group, 31% GM); D&W GM, CCC, ROIC, FCF conversion from FY25; net debt / EBITDA from H1 FY26 adjusted ($5.5m / $50m run-rate).

The standard FMCG ratios (operating margin, asset turnover, dividend yield) are not the right lens here. The question this business resolves to is whether the mix rotation from regulated vape to branded drinks/wellness happens at a rate that preserves group EBITDA. That is what these eight numbers track. Vape gross margin and Drinks & Wellness gross margin convergence are the two that move the stock; net debt / EBITDA tells you whether management can keep buying assets without diluting; CCC and FCF conversion tell you whether the unit growth is real cash or accounting bulk.

5. What Is This Business Worth?

The right valuation lens is one branded-FMCG platform with a segment-mix overlay — not strict sum-of-the-parts, because the segments are run from one warehouse, one ABL facility, and one sales force, and you cannot sell vaping without selling the platform. But the segments do deserve different multiples, and the consolidated EV/EBITDA hides that.

An indicative segment lens (illustrative only — Supreme does not disclose segment EBITDA, so the split below allocates group Adj EBITDA by gross-profit share, which understates vape and overstates drinks):

The cleaner way to underwrite is to ask three questions. First, is the underlying ROIC durable? Five-year ROIC has held above 27% through a doubling of revenue and three substantial acquisitions; that is best-in-peer-set. Second, is the FCF real? FY25 FCF/EBITDA was 53% on growing capex; H1 FY26 operating cash dropped to $5m mostly on freight-shift working capital — needs to unwind. Third, what does management do with cash? They are reinvesting at deal multiples that look inside 1.5x revenue (Clearly Drinks $19m on $40m+ revenue, SlimFast $26m on ~$26m run-rate revenue, 1001 $2.2m + earnouts on a heritage carpet brand). If those acquisition multiples convert to group ROIC over 24-36 months, the platform value is in the $355m+ range — if.

6. What I'd Tell a Young Analyst

Don't anchor on "AIM-listed UK FMCG." Anchor on segment economics. Supreme blends a 36%-GM regulated category, a 29%-GM growing branded category and a 20%-GM declining one. The consolidated 32% GM is meaningless without the mix; track each one separately and the group story comes into focus.

The two numbers that move the stock are vape gross margin and the disposable runoff. Disposable revenue is essentially zero now — that fight is done, and the stock has not rerated for it. Vape GM compressed 200bps in H1 FY26 in the pod transition; the question is whether that is a one-time reset or the start of a slide. Watch the H2 FY26 print and the first post-duty disclosure (FY27 H1).

Working-capital days are the early-warning system. A platform that compounds revenue 20% over five years on a $54m ABL facility either converts well or it doesn't. CCC at 61 days in FY25 says it does. If the H1 FY26 working-capital outflow does not unwind by year-end, you have a quality problem the headline EBITDA will hide.

The M&A engine is the actual investment thesis. Supreme is a UK consolidation play sized like a small-cap vape stock. Five deals in 18 months at sub-1.5x revenue, financed off-balance-sheet through an ABL that has $46m undrawn. If management cannot keep that cadence, 5x EV/EBITDA is fair; if they can, the implied multiple is 7-8x.

What would change the thesis. Equity raise to fund the next deal (dilutes the per-share story); a regulatory restriction on vape flavours under the new bill (compresses the engine that funds the rotation); ABL covenant breach (forces working-capital discipline at the worst time). None is a base case; all are observable in single RNS prints. Read every RNS announcement; this is not a stock you valuation-screen and forget.

Competition — Who Can Hurt Supreme, and Who It Can Beat

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Competitive Bottom Line

Supreme has a real but narrow moat: it is the only UK-listed company running a vertically integrated, multi-category, value-channel branded FMCG platform — manufacturing, brand-licensing, brand-owning, and distributing simultaneously through one Manchester hub into ~3,300 trade accounts across grocery, variety-discount, convenience, cash-and-carry and export. The defensible asset is the system, not any single product: pull out vaping or sports nutrition individually and larger or sharper players win on brand and scale. The competitor that matters most is Imperial Brands — not because IMB will displace Supreme on a B&M shelf, but because IMB's blu (UK vape share above 10%) and its pricing behaviour around the 1 October 2026 vape duty set the wholesale margin Supreme's profit engine resolves to.

The Right Peer Set

Supreme's peer problem is that no public company looks like it. The five peers used here cover Supreme by economic exposure, not by index basket: NICL is the soft-drinks pure-play, APN the sports-nutrition pure-play, IMB the vape category benchmark, PFD the closest multi-category UK branded FMCG template, and HFG the broad UK-FMCG-to-retail channel reference (weakest direct overlap, retained for breadth). All five report in GBP. Fiscal year-ends differ (SUP March, NICL Dec, PFD March, IMB Sep, APN July, HFG Dec) so cross-period reads need fiscal alignment.

Market caps and EVs as of 2026-05-08 (HFG patched manually 2026-04-30 from public web; net debt unavailable from source so EV shown as N/A). Latest FY revenue uses each peer's FY2025 reporting period, converted at period-end GBP/USD rate. Source: peer Fiscal.ai snapshots, peer FY2025 annual reports, peer_valuations.json.

Why this peer set is right. No single company spans Supreme's three categories, so a single-peer multiple is meaningless. NICL covers the soft-drinks economics (asset-light bottling, brand-driven, 46% GM). APN covers the sports-nutrition economics (single-factory, 27% EBITDA margin, 47% UK growth). IMB sets the vape-category framework (regulation, NGP scale, blu UK share >10%). PFD shows what a mature, multi-category UK branded FMCG platform looks like at scale. HFG is the deliberate negative control — a $5.7bn revenue UK-FMCG-to-retail business with 4% EBITDA margin and a single customer (Tesco) that takes 33% of revenue, illustrating the alternative customer-concentration risk Supreme is actively trying to avoid.

Rejected and why: AG Barr (BAG) — strong UK soft-drinks comp but redundant given NICL covers Vimto/squash/RTD. PZ Cussons (PZC) — strong UK FMCG personal care/household fit, but Fiscal.ai 404'd; IR-site-only stage deferred. Britvic (BVIC) — acquired by Carlsberg in 2025, no longer listed. Science in Sport (SIS) — micro-cap with persistent losses, less informative than APN. McBride (MCB) — UK private-label cleaning, economics diverge from Supreme's branded-distribution model.

Where The Company Wins

Four concrete advantages stand up against this peer set, each with a measurable signature.

The platform-economics advantage is the headline takeaway. Supreme's 31.9% blended gross margin is well above IMB (21.8%) and PFD (38.2%, but on much larger asset base) — and within striking distance of NICL/APN — while it is doing four times as many things at once. The honest read: SUP is not best-in-class on any single category, but no peer can match the breadth of categories run at SUP's gross-margin level on its $39m PP&E base.

Where Competitors Are Better

Supreme's peer set highlights four real weaknesses. None is fatal; together they are the reason the rerating gap to NICL/APN multiples may not close on its own.

The honest summary of the weakness column: Supreme is a platform, not a brand. APN, NICL and PFD make more per pound of revenue because each does one thing very well; IMB has scale; HFG has long-term retailer contracts. Supreme's defence is that doing four things passably is harder to copy than doing one thing brilliantly — but that defence has to be re-earned every year through continued M&A integration and category mix discipline.

Threat Map

Moat Watchpoints

These are the five measurable signals that will tell an investor whether Supreme's competitive position is improving, holding, or deteriorating over the next 12-24 months. Each is observable in a public filing or industry data source.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Current Setup & Catalysts

1. Current Setup in One Page

The stock is trading around $2.21, three weeks after a 20 April 2026 trading update that printed FY26 revenue of c.$365M and Adjusted EBITDA of c.$55.9M — both significantly ahead of consensus ($337M / $51M), with vape sales +10% YoY despite the 1 June 2025 disposable ban. The market is now watching vape gross margin in H1 FY27 (November 2026), the first interim disclosure after the $3.00/10ml Vaping Products Duty takes effect on 1 October 2026. The operating print undercuts the "permanent demand destruction" leg of the bear thesis, but the tape has not confirmed it: a death cross from 26 November 2025 remains in force and the most recent insider trade was the CEO's $4.09M sale at $2.13. Today (8 May 2026) the Tobacco and Vapes Act 2026 received Royal Assent, opening a soft-window risk on flavour/packaging secondary legislation. The event path is dense: FY26 final results in early July 2026, AGM in September, vape duty on 1 October, H1 FY27 in November.

Recent setup rating: Bullish.

---

2. What Changed in the Last 3–6 Months

Recent narrative arc. Through Q3 2025 the market was underwriting Supreme as a structurally-declining vape distributor with a CEO selling stock and working capital absorbing cash. By April 2026 that picture had inverted: the FY26 trading update flushed out the "demand destruction" worry, the H2 working-capital absorption reversed (net cash at 31 March 2026), and the M&A engine added Carabao energy on top of SlimFast. What has not been resolved is the second leg — the 1 October 2026 Vaping Products Duty, which hits the highest-margin segment Supreme has not yet been forced to test. The story has shifted from "is demand still there?" (answered: yes) to "what does the wholesale margin look like when the duty goes live?" (answer: November 2026 reveals it).

---

3. What the Market Is Watching Now

The live debate has narrowed to four specific questions. Each has a clear marker.

A fifth, slower watch is the timing of the first flavour/packaging consultation under the Tobacco and Vapes Act 2026, which received Royal Assent today (8 May 2026). No public timeline has been published; this is a soft-window overhang rather than a near-term catalyst.

---

4. Ranked Catalyst Timeline

Ranked by decision value to a fundamental investor, not chronology.

---

5. Impact Matrix

The catalysts that actually resolve the bull/bear debate, ranked by how much they move the underwriting.

---

6. Next 90 Days

The 90-day window (8 May → 6 Aug 2026) is dominated by one hard date — the FY26 final results in early July — and one soft window: the Tobacco and Vapes Act secondary-legislation consultation can open at any point now that Royal Assent has landed.

The first event that genuinely moves the debate — the 1 October 2026 vape duty and the 25 November 2026 H1 FY27 print — sit beyond 90 days. Inside the window, the FY26 final is a confirmation event for the trading update, not a thesis-resolver.

---

7. What Would Change the View

Three observable signals would force the bull/bear debate to update over the next six months. First, the H1 FY27 vape gross margin in November 2026 — pod GM at ≥30% post-duty removes the central reason the multiple is compressed and would set up a re-rating toward the 7.5x peer median; pod GM under 28% confirms the bear's 4.5x EV/EBITDA framework. Second, the FY26 cash-flow statement in early July 2026 — audited proof that H2 working-capital reversed (consistent with the trading update's "net cash" claim) closes the forensic gap that made the bear thesis credible at the H1 print; if cash conversion stays below 80%, the M&A engine's "FCF after acquisitions" math (negative $4.8M in FY25) becomes the structural bear case. Third, a flavour/packaging consultation under the Tobacco and Vapes Act 2026 with wide scope would re-open the "permanent demand destruction" debate that the 20 April 2026 trading update has just closed — and it can land any week from now. None of these are Stan's verdict; they are the events that force the update.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — the decisive variable is dated, observable, and only ten months away. Bull and Bear converge on the same trigger from opposite directions: the H1 FY27 vape gross margin print in November 2026, the first disclosure after the $3.00/10ml duty takes effect on 1 October 2026. Bull says a 5.0x EV/EBITDA, 30% ROIC, founder-controlled platform with five disciplined sub-1.5x-revenue bolt-ons is mispriced versus a 7.6x UK FMCG peer median; Bear says the platform is a leveraged FCF mirage where 56% of revenue is regulated, ~30% is brand-rented from Heaven Gifts, and pod gross margin already compressed 200bps pre-duty. The single tension that resolves it is whether the H1 FY26 pod-margin compression was a one-time pod-transition reset or the leading edge of a structural slide. Sizing before that print captures any rerating tail; waiting trades that optionality for resolution of a knowable binary in the highest-margin segment. We lean Bull on quality and ownership signals, but the patient call is to size after November 2026.

Bull Case

Bull target: $3.27 (12-18 months). Method: 7.0x EV/EBITDA on FY27e Adjusted EBITDA of $57.2m (FY26 guide $55.3m plus Drinks and Wellness gross-margin convergence on the annualised SlimFast/Carabao base) → $400m EV less $16.3m net debt = $384m equity ÷ 117.3m shares ≈ $3.27. The 7.0x multiple is a 60bps discount to UK FMCG peers, leaving the vape regulatory premium intact. Primary catalyst: H1 FY27 disclosure in November 2026 — first vape gross margin print after the 1 October 2026 duty. Pod GM at or above 30% removes the central reason the multiple is compressed. Disconfirming signal: vape gross margin printing under 28% in H1 FY27 (compression is structural, not transitional), or any equity placing to fund the next acquisition.

Bear Case

Bear downside: $1.50 (12-15 months, −32%). Method: vape GM compresses 5pp post-duty (31% H1 FY26 → 26%, retailer refuses full pass-through), wiping ~$8.2m of EBITDA. Strip the $5.3m Typhoo bargain gain from the $52.4m FY25 base. Run-rate Adj EBITDA settles at $40.9-43.6m. Apply 4.5x EV/EBITDA — the multiple a working-capital-stretched, ABL-funded, customer-concentrated FMCG distributor deserves — less $16.3m net debt ÷ 117.6m shares ≈ $1.49, round to $1.50. Primary trigger: H1 FY27 vape gross margin printing under 28%, or an equity raise to fund the next acquisition. Cover signal: H1 FY27 vape pod GM holds above 30% AND H1 FY27 OCF exceeds $20.4m — both prints together (showing the working-capital absorption was a one-off freight-shift, not structural).

The Real Debate

Verdict

Watchlist. The bull case carries slightly more weight on the structural inputs — 30% ROIC, 5.0x EV/EBITDA versus a 7.6x peer median, founder skin of 54.27% with $140m at risk, and a forensic-leaning long fund (Bronte Capital) adding 12.66% to its position — but the bear has identified the one piece of new information the bull cannot dismiss: pod gross margin compressed 200bps in H1 FY26 before the $3.00/10ml duty. That single fact is the tension that resolves the rest of the debate, because it determines whether the highest-margin slice of a 56%-regulated revenue base is structurally pressured or just transitioning between formats. The bear could still be right if H1 FY27 vape GM prints under 28% or an equity placing arrives to fund the next deal; the cash-conversion ledger is genuinely stretched, with FCF after acquisitions of −$4.8m in FY25 and 3-year true conversion of just 34%. The verdict changes to Lean Long if H1 FY27 vape pod GM prints at or above 30% AND H1 FY27 OCF exceeds $20.4m on the same release; it changes to Avoid if pod GM prints under 28%, or if Supreme issues equity to fund a deal before that print arrives. Sizing before November 2026 forfeits a knowable binary disclosure for a multiple-expansion call available after the print at modest cost in upside.

Moat — What Protects This Business, If Anything

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

1. Moat in One Page

Conclusion: narrow moat. Supreme has a real but limited economic advantage. The moat is the distribution system — one Manchester warehouse + ~3,300 trade accounts + ~50,000 retail outlets + a portfolio of long-running exclusive brand licences (Energizer batteries, JCB, Black+Decker lighting) — and a defended niche in value-priced vaping (88Vape with ~1.3m regular users plus the HMPPS prison contract). It is not a wide moat: the company is the smallest player in every individual category it serves, three of its four product engines are licensed or distributed (so renewal-dependent), and the highest-margin segment (vaping) is being reshaped by regulation it does not control.

A moat, in this context, is whatever lets Supreme keep ~30% ROIC and a 32% gross margin while running $39m of net PP&E across four unrelated FMCG categories — when a pure FMCG distributor (Bunzl, Kitwave) earns 5-10% gross and a single-category branded peer (Applied Nutrition, Nichols) cannot replicate the breadth. The honest read: the system is hard to copy, but no individual piece of it is.

Moat rating: Narrow. Weakest link: ElfBar/Lost Mary disintermediation risk.

The 2-3 strongest pieces of evidence. (i) Supreme services ~30% of the UK battery market through 50,000+ retail outlets with 300m+ batteries per year on the back of long-running Energizer, Duracell, Panasonic relationships and an exclusive JCB battery licence — that is a documented cost-and-distribution advantage no UK FMCG peer matches in the value channel. (ii) 88Vape has ~1.3m regular users (per Supreme's 13 Sep 2023 RNS) and an HMPPS prison-service contract estimated at ~$13m — an institutional-cessation niche tobacco majors have largely ceded. (iii) Five-year ROIC has held at 27-43% through a doubling of revenue and three substantial acquisitions, evidence that the platform absorbs new categories without diluting capital efficiency.

The 1-2 biggest weaknesses. (i) ~30% of FY25 vape revenue ($97m of $103m H1 FY26 core) flows through third-party brands (ElfBar, Lost Mary, IVG, Hayati) Supreme does not own — Heaven Gifts (ElfBar's owner) has a documented history of building direct distribution beachheads and could disintermediate. (ii) Brand equity in owned categories is several tiers below sector leaders — Premier Foods has 89% UK household penetration on Mr Kipling/Bisto; Nichols' Vimto is the #2 UK squash brand at $174m RSV; Supreme's owned brands (88Vape, Sci-MX, Typhoo, SlimFast) sit in the second/third tier within their categories.

---

2. Sources of Advantage

The job here is to test specific, named moat sources — not adjectives. Of the nine standard moat categories, four are visibly evidenced at Supreme, three are partially evidenced, and two do not apply.

Term primer. Switching costs are the cost / risk / disruption a customer faces in changing supplier. Network effects exist when each new user makes the product more valuable to other users. Cost advantage is a structurally lower unit cost (scale, density, location, integration). Intangible assets are brands, patents, licences, regulatory permissions whose ownership generates pricing power. Distribution advantage is privileged access to channels competitors cannot easily replicate.

The four sources that pass the proof bar are distribution density (high), brand-licence portfolio (medium-high), 88Vape niche + HMPPS contract (medium), and vertical-integration scope (medium). The remaining categories are either absent (no network effects, no patents) or low-quality moats (capital intensity, retailer switching costs).

---

3. Evidence the Moat Works

A moat that does not show up in numbers is not a moat. The evidence below tests whether Supreme's claimed advantages produce measurable economic outcomes — and looks for evidence that refutes the moat.

The ROIC chart is the cleanest single piece of evidence the moat works at the system level — it would dilute fast for a company without a real platform advantage adding categories at this pace.

---

4. Where the Moat Is Weak or Unproven

Three weaknesses do not break the narrow-moat conclusion but they should keep an investor sceptical of the wide-moat reading the share-price implies if it ever closes the peer gap.

Brand equity is shallow in every owned category. Premier Foods discloses 89% UK household penetration on Mr Kipling/Bisto/Ambrosia/Batchelors; Nichols' Vimto is the #2 UK squash brand at $174m RSV; Imperial Brands' blu has UK vapour share above 10%. Supreme's owned brands (88Vape, Sci-MX, Battle Bites, Sealions, the recently acquired Typhoo and SlimFast) sit several tiers below sector leaders on top-of-mind awareness. The defence is aggregate brand portfolio, not any one trademark — which is exactly why a Glanbia-style strategic acquirer of Applied Nutrition would still outclass Supreme on owned-brand pull.

~30% of vape revenue is a rented relationship. ElfBar and Lost Mary (Heaven Gifts brands) generated 2.5m units sold per week in the UK and ~$51m of FY24 revenue under Supreme's master-distributor agreement. The same Reuters investigation that gives the 2.5m number documents Heaven Gifts' history of "establishing a distribution beachhead" before going direct in the US — the company built Deepvaping.com to sell direct-to-consumer and direct-to-retailer once it knew the channel. There is no public disclosure of the term length of Supreme's master-distributor agreement; the loss event is binary and observable.

The "platform breadth" defence has not been stress-tested at full mix-rotation. Supreme has graduated three times in five years — 5-division FMCG (FY21-22), vape pure-play in waiting (FY23-24), re-diversified roll-up (FY25-26). Each pivot was forced by a tailwind ending. The platform absorbed those pivots, but the test of whether breadth is a moat or simply a good operating capability is the next regulatory shock — the 1 October 2026 vape duty and the secondary legislation on flavours/packaging under the Tobacco and Vapes Bill (royal assent Apr 2026). If group EBITDA holds at ~$52m through that transition, breadth is a moat. If it doesn't, breadth is just diversification.

The distribution moat may be channel-specific, not company-specific. Supreme's defensible position is the variety-discount channel (B&M, Home Bargains, Poundland) which has become 25-30% of UK FMCG growth over the last five years. But Oliver Wyman estimates this channel will grow ~30% by 2028 and become a "priority channel" for FMCG companies generally — meaning the channel is becoming more attractive to larger competitors (PFD, IMB, AG Barr) who can afford slotting fees Supreme cannot match.

---

5. Moat vs Competitors

Supreme's peer problem is that no public company looks like it. The peers below cover Supreme by economic exposure, not index basket — and the comparison is structurally unfair because each peer competes with one of Supreme's segments, not with the system. The honest read: Supreme does every individual thing worse than the relevant peer; it is the combination that no peer matches.

Author scoring of moat-axis strength on a 0-100 relative basis; channel depth = combined breadth of UK trade-account and retail-outlet reach. Bubble size = market cap.

The peer-moat read is structural: Supreme is the only name in the set that scores above 50 on more than one axis without being a global major. IMB scores high on three axes (brand, channel, licence) but is one-category. PFD scores high on brand and channel but has no licence portfolio worth speaking of. APN, NICL and HFG each score high on a single axis. Supreme's 60/35/70/50 profile is moderate everywhere and dominant nowhere — which is the exact shape of a narrow moat.

---

6. Durability Under Stress

A moat only matters if it survives stress. Below are the seven stress cases that would test Supreme's narrow moat in the next 24-36 months. Each is observable in a single filing or trade-press print.

The two stress cases that break the narrow-moat conclusion are Energizer/JCB licence loss (compromises the cost-advantage / brand-licence moat directly) and Heaven Gifts disintermediation (compromises ~30% of vape revenue). The remaining five cases compress earnings but leave the moat intact. That asymmetry is the right way to think about Supreme: it is one or two specific events away from being a "moat not proven" rather than "narrow moat" company.

---

7. Where Supreme PLC Fits

The moat is concentrated in specific parts of the business, not the consolidated entity. A beginner investor who reads the FY25 group accounts ($299m revenue, 31.9% GM, 30% ROIC) without segment-level discrimination will overpay — and the multiple already reflects that, which is why the discount is there.

The protected segment is Electricals — the segment trading at the lowest multiple. Electricals (~23% of revenue, declining 6%/year, ~20% gross margin) has the most defensible moat in the group: 30+ years of Energizer/Duracell relationships, an exclusive JCB battery licence, and ~30% UK market share. The market values it as a melting cash floor; the moat work suggests it is the most durable piece of the platform — a quiet asymmetry that supports the $349-414m SOTP estimate from the business-claude.md analysis.

The unprotected-but-most-valuable segment is Vaping. Vape is 56% of revenue, ~36% FY25 gross margin, the bulk of group EBITDA — and the segment with the most regulatory and disintermediation risk. Vape has some moat (88Vape brand, HMPPS contract, compliance scale) but ~30% is rented from Heaven Gifts. The market is right to discount it, and the moat work agrees.

Drinks & Wellness is where the moat thesis gets underwritten, not where it currently lives. $260m+ of M&A spend is creating a new branded-FMCG platform; whether it generates a moat depends on Drinks & Wellness gross margin converging toward 33%+ by FY27 and brand equity in Typhoo/SlimFast lifting beyond tier-2. Today this segment is moat-not-proven.

---

8. What to Watch

These are the five measurable signals that will tell an investor whether Supreme's narrow moat is widening, holding, or narrowing further over the next 12-24 months. Each is observable in a public filing or trade-press print.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Forensic Verdict

Supreme is a Watch with credible Elevated drift. Reported five-year cash conversion is clean (CFO/Net income of 1.17 over FY2021-FY2025) and the FY2025 audit report was unqualified with no emphasis-of-matter paragraph and no non-audit fees. But three signals deserve underwriting: (1) acquisition-adjusted free cash flow turned negative in FY2025 ($33.2m of M&A absorbed all operating cash), (2) inventory grew 49% and receivables grew 18% on revenue growth of just 4% in FY2025, with the working-capital pressure intensifying in H1 FY2026 (operating cash flow collapsed to $5.1m from $15.1m), and (3) trade receivables and inventory are pledged to HSBC under the new Asset-Based Lending facility and the company pays "invoice discounting fees" ($557k FY2025) — confirming factoring is part of the cash machine. The grade would downgrade to Elevated if H2 FY2026 working capital does not normalise; it would upgrade to Clean if FY2026 reduces inventory days back below 60 and receivables sales fall away.

13-Shenanigan Scorecard

Of the 13 categories, four register red (factoring of receivables, acquisition-driven CFO flattering, working-capital lifeline, and the headline metric/cash conversion gap), five register yellow, and four are clean. The red flags cluster on cash-flow quality and the M&A-driven story, not on income-statement fabrication.

Breeding Ground

The structural conditions at Supreme are mixed: a controlling founder-CEO with operational dominance against an independent-majority Board, a single-metric bonus plan that recently shortened from three years to one, and an audit relationship that is clean on independence but has only been audited under increasing scope as M&A scales.

The breeding ground does not amplify the cash-flow red flags into critical territory. Independent NEDs and the audit committee provide real challenge, fees and behaviour at the auditor look clean, and there are no related-party customers. What does amplify risk is the alignment between (a) a 56%-controlling founder-CEO who personally drives M&A, (b) a bonus plan now anchored on a one-year Adjusted EBITDA target, and (c) a metric that benefits from acquisition timing and bargain-purchase accounting. That combination warrants the "Watch" grade rather than "Clean".

Earnings Quality

Earnings quality is mostly clean on the income-statement side, weaker on the balance-sheet side. Gross margin expanded to 32% from 29% (mix shift towards manufacturing-margin Clearly Drinks and away from low-margin disposables), reserves are not visibly being released, and there is no big-bath impairment pattern. The pressure point is receivables and inventory growing materially faster than revenue.

In FY2024, receivables grew 70.5% as revenue grew 42.2% — a 28-point gap as the disposable-vape windfall and acquisitions both fed AR. In FY2025, the pattern reverses for inventory: with revenue growth slowing to 4.4%, inventory grew 48.7%, a 44-point gap, as Typhoo and Clearly Drinks stocks consolidated and the disposable vape ban (1 June 2025) drove pre-emptive non-disposable inventory. Management's explanation is plausible, but the H1 FY2026 filing shows inventory rising further to $57.3m (six months later) — the working-capital absorption is not just a year-end optical issue.

DSO ended FY2025 at 67 days, the highest since FY2020 and 18 days above FY2023. DIO at 84 days is the highest since FY2022 and 27 days above FY2024. Payables (DPO) extended to 78 days from 63, partially funding the build — a working-capital lever that is sustainable until suppliers push back. The cash conversion cycle widened 21 days in a single year (52 days in FY2024 to 73 days in FY2025).

Reported PBT of $40.0m in FY2025 includes a $5.3m non-cash bargain-purchase gain on the Typhoo administration deal. Stripping that out reduces PBT to roughly $34.7m, materially below the FY2024 figure of $38.1m. Adjusted PBT of $39.1m (down 2% YoY) tells the cleaner underlying story — and, on that lens, FY2025 was a flat-to-down year, not a "+3%" year.

Cash Flow Quality

Reported headline cash conversion looks strong (5-year CFO/Net Income of 1.17 and FCF/Net Income of 1.02). The forensic concern is what happens after deal spend.

FY2025 is the standout year: free cash flow after acquisitions swung to negative $4.8m as the $33.2m M&A bill (Clearly Drinks $19.7m + Typhoo $13.2m) absorbed the entire $28.4m of post-capex free cash flow. Three-year cumulative FCF after acquisitions (FY2023-FY2025) is $25.4m on cumulative net income of $73.5m — a 35% true-cash-conversion ratio that is materially worse than the 1.07x FCF/NI headline.

Working capital was an $8.9m drag on CFO in FY2025 — and a $14.8m drag in H1 FY2026 alone. Pre-working-capital cash flow ($41m FY25) is healthy and grew strongly, but the gap between "what the business earns" and "what the business converts to cash" is widening as inventory and receivables consume the increment.

The structural shift from a Revolving Credit Facility to an Asset-Based Lending facility in March 2025 is a quiet but meaningful change: ABL pricing tracks the borrowing base (debtors + inventory), so factoring/discounting volume becomes a built-in feature of the funding stack, not an exception. $557k of invoice discounting fees in FY2025, $105k in H1 FY2026, is small relative to operating cash flow but proves the mechanism is live.

Metric Hygiene

Adjusted EBITDA is the single most important metric for Supreme — it sets 80% of executive bonuses, anchors the consensus figure ("FY26 consensus $50m Adjusted EBITDA"), and is the only profitability metric in the half-year highlights table. Investors should treat its construction with care.

The Adjusted earnings premium over GAAP net income has narrowed from 17% in FY2023 to 8% in FY2025 — a positive signal that adjustments are not widening as scale grows. The gap is small in absolute terms ($2.4m in FY25), so non-GAAP risk is contained even though the framing is favourable.

What to Underwrite Next

Five concrete diligence items will move the forensic grade in either direction over the next two reporting periods.

The forensic call. Supreme's accounting risk is a valuation haircut and a position-sizing limiter, not a thesis breaker. The numbers are not visibly fabricated; the audit is clean; the income statement reflects a real, growing FMCG business with margin expansion. But the mechanism behind reported "another highly cash-generative year" in FY2025 is a stretched working-capital cycle, factoring of receivables, and acquisitions consuming all of the post-capex cash. Underwriters should (i) discount the Adjusted EBITDA number when valuing on a multiple — apply at minimum a $5m haircut for the bargain-purchase gain — and (ii) require a CFO-to-Adjusted-EBITDA ratio of at least 0.55 (vs FY25's 0.62) to maintain conviction. If H2 FY2026 fails to recapture the working-capital outflow, the grade moves to Elevated and the position thesis tightens.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Management & Governance

Supreme is a founder-controlled AIM company where one man — Sandy Chadha — owns 54% of the equity, runs the business, and sets the deal cadence. The governance grade is B: alignment is genuine and audit hygiene is clean, but the board is small, the long-term incentive plan was weakened in FY25, and minority shareholders have no voting leverage.

Governance Grade: B. Founder-controlled with strong skin in the game; weakened LTIP and de-minimis NED holdings keep it from A territory.

1. The People Running This Company

A five-person board oversees a $310M+ revenue group that has completed eight acquisitions since IPO. The line-up is unusually narrow but the relevant experience is concentrated where it matters: founder-CEO, M&A NED, distribution-CEO NED, and a Chair who has done a UK-listed refinancing before.

Two observations matter. First, Chadha is the company — he is the largest shareholder by a factor of seven over the next holder, runs M&A himself, and his commentary dominates the trading updates. Second, succession planning is a flagged board topic in the FY25 evaluation — not a crisis, but a known gap that the Chair has not yet closed.

2. What They Get Paid

Pay is modest by main-market standards and explicitly tied to Adjusted EBITDA — which in FY25 hit target in full, triggering a 93.33% of maximum payout for both executives. The structural choices are more interesting than the headline numbers.

Three things stand out. First, the CFO out-earned the CEO this year — Smith took home $832k vs Chadha's $818k — because her Supreme Incentive Plan award was 200% of salary potential whilst Chadha's 100%-of-salary cap reflects his existing shareholding. That's defensible. Second, the CEO's entire bonus is paid in cash, not deferred shares, "recognising his existing shareholding". This is a missed opportunity to ratchet alignment further given the FY26 transition. Third, the LTIP was scrapped in FY25 and replaced by an annually-measured Supreme Incentive Plan because the Committee found "long-term targets too hard to set". The 50/50 cash-shares deferral preserves some retention value, but in pure governance terms this is a regression: 80% of variable pay is now Adjusted EBITDA — a metric that mechanically rises with the next acquisition.

3. Are They Aligned?

Sandy Chadha has approximately $141M of personal wealth tied up in Supreme stock — roughly 172× his annual cash compensation. That is alignment of an order rarely seen in UK public markets. Everyone else is along for the ride.

Ownership

Public float is 14.3% — extremely tight. Bronte Capital, an Australian fundamental investor known for both long bets and forensic short work, has been adding (+12.66% to its position over six months to 31 March 2026), which is worth flagging as an external validation rather than a red flag. Stiskin's 7.62% block is an opaque but stable individual holding.

Director Holdings vs Pay

The CFO holds 39,656 shares — about $87k at the prevailing price. For an executive who has been in seat through an IPO and eight acquisitions, that is materially under-aligned, and the FY25 SIP partially fixes this by deferring 50% into shares vesting over three years. The NEDs hold token positions of 30k–60k shares each. Outside the founder, this board is paid, not invested.

Insider Activity

Chadha sold 2,000,000 shares — about 3% of his holding — in November 2025 at $2.11, raising $4.2M. The first material insider sale on file. Two readings are reasonable: (a) routine partial monetisation by a 57-year-old founder still holding 54% and (b) a top-tick signal four months after the share price rolled over from $2.79. The price post-sale is roughly flat, so it has not yet looked like alpha. Worth tracking for repeats.

Dilution and Capital Allocation

Outstanding executive options total 3,244,666 shares (Chadha 2,912,500 IPO options expiring FY26 plus Smith 332,166 SIP/LTIP) — roughly 2.8% potential dilution, modest by AIM standards. The board has paid a dividend every year since IPO at ~25% of profit-after-tax payout, and has prioritised debt-funded M&A over buybacks. Eight acquisitions in five years is aggressive; that pace is the single biggest governance risk because Adjusted-EBITDA-weighted bonuses make integration discipline a personal pay question for the executives.

Related-Party Behaviour

The proxy text discloses no material related-party transactions, no service contracts with Chadha-affiliated entities, and no property leases involving directors. Auditor non-audit fees are zero. A relationship agreement exists between the company and Chadha as controlling shareholder — standard AIM protection but only as good as the independent directors enforcing it.

Skin-in-the-Game Score: 7 / 10

Pulled up by Chadha's $141M stake. Pulled down by (a) the CEO's bonus paid all-cash from FY26, (b) de-minimis NED and CFO holdings, and (c) the LTIP-to-annual-SIP downgrade.

4. Board Quality

Five directors, three of whom the company classifies as independent. The Chair / CEO split exists, the Audit Committee has accepted no non-audit work from the auditor, and an external facilitator ran the FY25 board evaluation for the first time. By QCA Code standards (the lighter AIM regime, not the full UK Corporate Governance Code) the box-ticking is in order.

Board skills coverage — "Yes" = strong relevant experience; "—" = gap.

The skills map exposes two real gaps. First, no NED has direct FMCG operating experience. The independent directors come from distribution (Cashmore at Smiths News), corporate finance (Lord), and value retail (McDonald) — adjacent, not the same. As Supreme moves from a vape distributor into branded grocery (Typhoo, SlimFast) the strategic gap will widen unless a category-experienced NED is added. Second, the board is just five people. That is QCA-compliant but thin: a single resignation would leave Audit and Remuneration covered by the same two NEDs.

The Remuneration Committee's decision to scrap the LTIP and consolidate into an annually-measured plan was consulted with key shareholders — that consultation process, and the QCA-compliant disclosure of it, is appropriate. The decision itself trades governance optics for retention pragmatism.

5. The Verdict

Grade: B. Founder-controlled, founder-aligned, audit-clean — but minorities have no voting leverage, the board is small, and FY25 weakened the long-term incentive structure rather than strengthened it.

What is genuinely good. A founder with 54% of his net worth in the stock; a Chair who has done the AIM-to-Main-Market refinancing playbook before at B&M; clean audit hygiene; modest pay for a $310M-revenue group; engagement with shareholders before changing the incentive plan; a relationship agreement in place since IPO.

What is genuinely concerning. The Supreme Incentive Plan replaced the LTIP because long-term targets are "hard to set" for a serial acquirer — but that is precisely the company that needs them. 80% Adjusted-EBITDA weighting plus an aggressive M&A cadence means executives get paid for buying revenue. The CEO's bonus is paid all-cash from FY26 onwards. The CFO and the three NEDs together hold less than $360k of stock. The board is five people deep with no FMCG operator amongst the NEDs. Public float is 14.3%, so a single institutional exit can move the price hard.

What would upgrade this to A-. Reinstate a 3-year LTIP for both executives with a TSR component; add a non-executive with branded-FMCG operating experience (the Typhoo/SlimFast strategy needs it); have the CEO's bonus deferred into shares for at least three years rather than paid in cash; a buyback of the small CFO/NED stock holdings to put more shares in directors' hands.

What would downgrade it to C+. A second material Chadha sell-down inside 12 months; a related-party transaction involving a Chadha family entity; an Adjusted-EBITDA-driven SIP payout in a year when shareholders see value destruction from a poor acquisition; or a Bronte Capital pivot from long to public-short.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Narrative Arc

In the four years since Supreme listed on AIM in February 2021, management has run three different strategies under the same logo: a five-division FMCG distributor (FY21–22), a vaping pure-play in waiting (FY23–24), and — once the disposable-vape ban arrived — a re-diversified consumer-brands roll-up (FY25–26). Operationally the team has executed: revenue grew 2.5x to $299m, Adjusted EBITDA more than doubled, and the FY24 ElfBar/Lost Mary windfall was caught and extracted before regulation closed it. But the narrative discipline is weaker. The dividend policy was halved within eighteen months of IPO, the FY23 print badly missed initial expectations, the "longer-term plan to retain" T-Juice ended seven months later, and "international expansion" has been promised every year and delivered in none. Credibility has been built on M&A execution, not on keeping the story straight.

Annotated timeline

What Management Emphasized — and Then Stopped Emphasizing

Reading the CEO reviews and risk sections back-to-back, three themes carried the IPO story, and three different themes carry the story today. The intensity heat-map below codes how often each theme appeared as a primary driver in the strategic report and CEO commentary.

Theme intensity by year (3 = primary driver, 0 = absent).

The dropped themes. The HFSS regulation tailwind was a centrepiece of the FY22 narrative (Battle Bites was "expected to drive sales as retailers seek to replace chocolate"). It vanishes from FY24 commentary. Branded Household Consumer Goods went from a category with growth potential to "non-core" before being repurposed as the reporting line for ElfBar. International expansion has been a stated growth pillar in every annual report from FY21 to FY24 — but the FY25 report removed it from the strategic priorities list, replacing it with "transformational M&A".

The "95% safer than smoking" framing, which appeared verbatim three times in the FY21–22 reports, has gradually been displaced by "credible, sustainable smoking cessation tool". The shift coincides with rising regulatory scrutiny — management did not abandon vaping, but quietly de-coupled the marketing language from the public-health claim.

Risk Evolution

The risk register tells a clearer story than the CEO reviews. Vaping went from a moderate concern (rated 10 in FY22) to the Group's largest single risk (25 in FY24 and FY25), even as it remained the largest profit pool. Other risks moved in interesting ways too.

Vaping risk doubled, then doubled again. In FY22 the discussion was about long-term health studies and product innovation — risk scored 10. In FY23, with the disposable-vape debate intensifying, the score jumped to 20. By FY24 the disposables ban was inevitable, the marketing-restrictions Bill was being drafted, and an excise duty had been announced — the score hit the maximum of 25, where it stayed in FY25 even after diversification reduced vape's share of the business.

What got safer. Raw material prices (whey, predominantly) were rated 16 in FY22 when prices were near 20-year highs; by FY24 they had retreated and the score fell to 6. Currency risk fell as more revenue moved to UK-domiciled brands. The single-site risk eased once the second Trafford Park warehouse (Ark) opened in FY24, then partially returned in FY25 as Clearly Drinks (Sunderland) and Typhoo (new UK plant) added geographies.

What got newly visible. Health & Safety risk rose from 9 to 12 in FY25 with the Group "now operat[ing] manufacturing from multiple sites … overseen by a single Health & Safety Manager." IT risk ticked up to 16 because the Typhoo acquisition "enhanced [the Group's] public profile, potentially making a more visible target for cyber attack" — a candid disclosure.

How They Handled Bad News

There have been three real disappointments since IPO: the FY23 Lighting collapse, the dividend-policy reversal, and the disposable-vape ban. The handling has been different in each case.

The Lighting collapse (FY22→FY23). Lighting revenue fell 43% from $35.4m to $19.0m as retailers worked off pandemic-era stockpiles. Management was direct about it, attributing the fall to a "temporary slowdown" and customer overstocking — and crucially noted that all listings and all customer relationships had been retained. The H1 FY23 print (Adj EBITDA -20% YoY, EPS -52%) was not sugar-coated. Recovery was promised across FY24-FY25; FY24 delivered a modest +7% rebound, but FY25 lighting fell again (-6% combined with batteries). The "temporary" framing was honest about FY23 but optimistic about the eventual ceiling.

The dividend cut. At IPO in February 2021, management promised "an aggregate annual amount equivalent to approximately 50% of net profits". By July 2022, eighteen months later, the policy was rebased to ~25%. The reframing in the FY23 H1 statement — "Supreme announced that it was revising its dividend policy to 25%" — was placed in the cash-flow notes rather than highlighted as a strategic shift. This is the cleanest example of a quietly walked-back IPO promise: it was not labelled as such.

The disposable-vape ban. In FY24 management was already pivoting language ("the potential short-term nature of this opportunity given the uncertainty of future legislation"), telegraphing the FY25 transition before it arrived. By the time the 1 June 2025 ban hit, management had already bought Clearly Drinks (June 2024) and Typhoo (November 2024), reducing vape concentration. The FY25 commentary was matter-of-fact: disposable revenue down $21m, no extensive stock provisions needed, transition managed. This was the most disciplined response — the diversification was telegraphed and executed in advance, even if the language about "an opportunity to reframe the commercial positioning" reads like a euphemism for "the regulator just took out a third of our revenue."

Guidance Track Record

Below is every promise or guidance number that meaningfully shaped the share-price reaction or capital-allocation decisions, with how it ended.

Pattern. When the in-house levers are working (FY22, FY24, FY25 EBITDA), management beats. When the macro turns against them (FY23, FY25 revenue), they miss. Their explanations have generally been honest about what went wrong. The promises that have aged worst are not the financial ones — they are the strategic-language ones (the dividend policy, international expansion, "longer-term plans" for individual brands).

Basis: Strong M&A execution; weak narrative discipline.

6/10 — earned upward, deserved downward. The team has compounded book value, made seven small acquisitions at attractive multiples (Sci-MX 9-month payback; Cuts Ice 4-month payback; Liberty Flights tracking to a 4-year payback; Clearly Drinks accretive in year one; Typhoo a $5.3m bargain-purchase gain), and called the disposable-vape ban early enough to diversify ahead of it. That is a 7+ on execution. But the dividend rebase, the FY23 miss, the pattern of "longer-term plans" being abandoned when better opportunities arise, and the quiet disappearance of multiple stated strategic priorities pull the number down. The CEO sacrificing his salary in H2 FY23 to fund cost-of-living pay rises pulled it back up by half a notch.

What the Story Is Now

The current pitch — confirmed in the H1 FY26 results in November 2025 — is that Supreme is no longer a vaping company that does some other things. It is a vertically-integrated FMCG roll-up where vape will fall to roughly half of revenue, with the other half coming from Drinks & Wellness (Clearly Drinks, Typhoo, SlimFast, Sci-MX) and a smaller Electricals & Household pillar (batteries, lighting, 1001). The platform — Manchester manufacturing, Ark distribution, ~10,000 retail outlets — is the thesis. The brands fit through it.

The single most useful quote from the entire five-year file appears in the FY25 CEO review, as the disposable-vape ban arrives:

"We view the forthcoming levy on vaping as an opportunity to reframe the commercial positioning of our vaping products."

That is exactly the right management-team instinct — when the world reframes against you, reframe with it — and exactly the kind of language a reader should learn to translate. "Reframe the commercial positioning" means "the old positioning no longer works." Investors who hear that as a positive should remember that Supreme's IPO commercial positioning was "leading multi-category FMCG", and within thirty months the dividend policy, the category split, and the strategic priorities had all been reframed too. Supreme is a good business run by a competent operator. It is not the same business it was at IPO, and management's preferred reframing is to change the story rather than to acknowledge that it changed.

Financials — What the Numbers Say

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

1. Financials in One Page

Supreme is a $299M-revenue UK consumer-staples distributor that has compounded the top line at roughly 20% per year for five years through a mix of category expansion and bolt-on acquisitions, while still throwing off cash. Operating margin (14.1%) and EBITDA margin (17.8%) sit in the middle of UK FMCG peers, but capital efficiency is exceptional: ROIC is around 30% and FCF converts at 94% of net income, because the model is asset-light branded distribution rather than capital-intensive manufacturing. The balance sheet carries only $16M of net debt (and is net cash on an IFRS-lease-adjusted basis) against $53M of EBITDA, giving Supreme firepower to keep buying complementary brands. Valuation is the loudest signal: the stock trades on roughly 8x earnings, 5x EV/EBITDA, and 9x free cash flow — a meaningful discount to UK consumer-staples peers (12-16x P/E, 8-10x EV/EBITDA), which the market is applying because Vaping (the largest category) is in a UK-regulation-driven transition. The single financial metric that matters most right now is non-disposable vaping revenue plus Drinks & Wellness — the test of whether the post-disposable-ban revenue mix can hold the $52m+ EBITDA line.

Quick definitions. Free cash flow is operating cash flow minus capex — what the business produces that owners can actually use. ROIC is after-tax operating profit divided by equity plus debt — the return the company earns on every dollar of capital invested in it. Net debt / EBITDA compares total debt minus cash to a year of operating cash earnings — under 1x is conservative, over 3x is stretched. EV/EBITDA is enterprise value (market cap + net debt) divided by EBITDA — the multiple a buyer of the whole company would be paying.

---

2. Revenue, Margins, and Earnings Power

Supreme's revenue has roughly tripled in five years — from $114m in FY20 (the year it listed on AIM) to $299m in FY25 — driven by category expansion (Sports Nutrition entered 2018, Vaping accelerated 2021-23, Drinks & Wellness was reshaped in 2024 with the Clearly Drinks and Typhoo Tea acquisitions). Operating profit doubled in the same window, but the path was uneven: FY23 saw a margin reset as Vaping disposable demand temporarily overwhelmed the cost base, and FY25 is a flat-revenue year as the UK disposable-vape ban (effective June 2025) was anticipated and the customer book pre-loaded.

The margin shape tells two stories. First, gross margin has stepped up from ~28% to ~32% — the 400bp gain in FY25 reflects Clearly Drinks adding in-house manufacturing rather than third-party distribution, plus a leaner mix as low-margin disposable vapes shrank. Second, operating margin has not moved as much because SG&A has grown faster than revenue in FY24-25 (people, head-office relocation to Trafford Park, and integration costs of three acquisitions). Investors should watch whether the gross-margin gain holds through FY26 — if it does, Supreme has a structurally better mix; if it reverts, the FY25 step-up was a one-off.

The H1/H2 view (Supreme reports semi-annually rather than quarterly) shows revenue is now flat-to-down on a like-for-like basis as Vaping rolls off, with H2 stronger than H1 — a seasonality pattern that has held through every reporting period. The earnings shape implies that for FY26 to grow at the guided +15% rate ($361m revenue, $55m adj EBITDA), the H1 print due in November 2026 has to clear ~$162m, ~10% above H1 FY25.

---

3. Cash Flow and Earnings Quality

Supreme converts profit to cash well. Over the last three years, free cash flow has averaged 96% of net income — a clean read that says the reported earnings are real money, not accruals. In FY25 OCF was $32.5m on $30.4m of net income (107% conversion); FCF was $28.4m, against capex of just $4.1m. That capex-light shape is structural — the company designs, brands, and distributes; it does not run heavy plant — and is what allows ROIC to stay near 30% even as the business scales.

The one wrinkle worth flagging is working capital. Receivables grew from $25.9m to $54.6m over FY23-FY25 (+111%) while revenue grew only 55%. Days-sales-outstanding has stretched from 47 days in FY23 to 61 days in FY25. Some of this is acquisition-related (Clearly Drinks and Typhoo carry their own receivables books), but it is also a reminder that Supreme sells through large UK retailers (Tesco, Sainsbury's, B&M, Home Bargains, Poundland) that have negotiating power on payment terms. Inventory is also building ($47.0m, +52% year-on-year), partly to pre-load customers ahead of the disposable ban. If receivables and inventory both keep growing faster than revenue, FCF/NI will compress below 80%.

---

4. Balance Sheet and Financial Resilience

Supreme runs a fortress-style balance sheet for its size. At March 2025, total debt was $20.0m (mostly the $52m revolver, only partially drawn) against $4.1m cash for net debt of $15.9m. Critically, on an "Adjusted net cash" basis (excluding IFRS-16 lease liabilities, which are operational rather than financial debt), the company is net cash positive at year-end despite spending $33.2m on acquisitions during FY25. Interest cover is wide (EBIT/interest ~18x) and the $52m facility was renewed in FY25 to fund continued M&A.

The notable balance-sheet feature is how little goodwill/intangibles Supreme carries despite an active M&A programme: only $27.5m, or 12% of total assets. Acquisition prices have generally been near-tangible-value (Typhoo $12.9m out of administration; Clearly Drinks bought late FY24). For comparison, Hilton Food carries goodwill at ~30% of assets and Premier Foods well above 50%. That means the balance sheet has not been inflated by overpaying for past deals — a quiet but important quality signal.

---

5. Returns, Reinvestment, and Capital Allocation

Returns on capital are the standout financial feature. ROIC has run at 27-43% every year since IPO and ROCE is in the same band. This is a function of the asset-light model — revenue runs through receivables, inventory, and a small PP&E base, with very little goodwill weighing down the denominator.

Note on FY20 ROE. Equity at IPO (Feb 2021) was tiny, so pre-IPO ROE figures (>200%) are not meaningful. ROIC, which has equity + debt in the denominator, gives a much cleaner read.

Capital allocation has been disciplined and acquisition-led. Over the last four years, management has spent $57m on acquisitions (Liberty Flights, Clearly Drinks, Typhoo, plus follow-ons) versus $23m on dividends and effectively zero on net buybacks. This is the right priority order for a sub-$325m revenue company that still has white space to add categories and own-manufacturing capacity. Share count has grown only ~2% per year (mostly from IPO and small placings); there is no equity-funded acquisition programme.

Per-share book value has compounded from $0.05 to $0.82 in five years — a 75% CAGR — even after returning ~$32m of cash via dividends. EPS has roughly doubled, FCF/share has held in the $0.18-$0.24 band despite the reinvestment programme. The dividend grew 10% YoY in FY25 to a 5.2p/share total (about a 32% payout of EPS, 28% of FCF), which leaves enough for the bolt-on M&A engine to keep running.

---

6. Segment and Unit Economics

Supreme reports a single IFRS segment but discloses revenue across three category groups (Vaping, Drinks & Wellness, Electricals — formerly five before the 2024 reorganisation). Profit by category is not separately disclosed.

Vaping is still the engine but it is changing shape. Disposable vapes were $70.0m in FY25 (down from $89.4m in FY24, a 23% decline) ahead of the UK government's June 2025 disposable ban. Non-disposables (88Vape own-brand plus distribution of branded reusables like Lost Mary and Elf Bar) grew 8% to ~$97m. The investment question is whether reusables can fully substitute for disposable revenue or whether there is a permanent step-down. Management's FY26 guidance ($361m group revenue, +15%) implies they believe the substitution holds and Drinks & Wellness can add another leg.

Drinks & Wellness is the new growth vector. It doubled to $63.2m in FY25 and management has added another tranche post-period (SlimFast acquired October 2025; Carabao Energy distribution agreement April 2026). On run-rate that is probably a $110-135m category for FY26.

Electricals is mature and managed for cash. Both batteries and lighting are in long-term volume decline, but Supreme outperforms the market thanks to scale advantages with B&M, Home Bargains, and Poundland. The category is the steady free-cash-flow contributor that funds M&A in the other two.

---

7. Valuation and Market Expectations

Valuation is the most interesting and disputable section of the page. At 162.5p (last close 7 May 2026, equivalent to roughly $2.21 at the spot rate), Supreme has a market cap of ~$260m and an enterprise value of ~$276m, giving a current-year multiple set that looks markedly cheaper than UK FMCG peers and cheaper than its own history.

The multiple compressed sharply in FY23 — when the disposable-vape uncertainty first hit — and has stayed compressed since. The current 8.1x P/E is half the 5-year average (~12x) and well below the 16-20x range Supreme traded at right after IPO. The market is paying for FY25 earnings as if they were peak earnings.

Look at the multiple alongside FY26 guidance. Management has guided to revenue of ~$361m (+15%) and adj EBITDA of ~$55m (essentially flat on FY25's $52m, because the higher-revenue/lower-margin acquisition mix dilutes EBITDA margin). That implies the forward P/E is broadly similar to current (~8x) and forward EV/EBITDA is ~5x.

Note that the valuation discount is deserved at the EBITDA level (UK regulatory uncertainty around vaping is real) and excessive at the FCF level (cash conversion has never been an issue, and the balance sheet is fine). The analyst that does the work to get comfortable on Vaping non-disposable substitution gets paid; the one that does not, doesn't.

---

8. Peer Financial Comparison

The peer gap that matters: Supreme has the third-highest ROIC in the set (after Nichols at 52% and Applied Nutrition at 33.6%) and the third-strongest balance sheet (after Nichols and Applied Nutrition, which both run net cash), yet trades at the second-lowest P/E and EV/EBITDA. The only peer that trades cheaper is Hilton Food, and Hilton has structurally inferior economics (2% operating margin, negative FCF, and material leverage). Premier Foods — the closest direct UK FMCG comparable — earns less than half Supreme's ROIC, has worse cash conversion, and trades at a 60%+ premium on EV/EBITDA. The peer gap is not justified by financial quality; it is justified, if at all, by the regulatory overhang on Vaping.

In the chart above, the natural rule "higher ROIC deserves higher EV/EBITDA" is broadly respected (NICL and APN cluster top-right). Supreme is the clear outlier — high ROIC, low EV/EBITDA. The market is offering ROIC of around 30% at a 5x multiple.

---

9. What to Watch in the Financials

What the financials confirm. Supreme is genuinely cash-generative, capital-light, and disciplined on acquisition pricing. The balance sheet has the firepower to keep doing bolt-ons through the next two years without re-leveraging. Returns on capital are top-quartile among UK consumer-staples peers. The valuation gap to peers is large enough to give a meaningful margin of safety on FY26 guidance.

What the financials contradict. The flat operating margin in FY25 versus the gross-margin step-up tells you SG&A grew unusually fast — not all of that is Trafford Park / acquisition integration; some is structural cost build that may not reverse. Receivables and inventory growing faster than revenue in FY25 is mild but worth tracking. Goodwill at ~12% of assets is fine for now, but the cumulative M&A pace (Clearly, Typhoo, SlimFast, Carabao distribution) means the forensic risk of pro-forma vs underlying revenue grows from here.

The first financial metric to watch is Vaping non-disposable revenue in the H1 FY26 (November 2026) results. If that line clears $55m for the half (implying ~$115m+ for the year), the disposable-ban transition is being substituted cleanly, FY26 guidance becomes credible, and the case for re-rating toward the peer median strengthens. If it lands below $48m, the FY26 EBITDA target is at risk and the current multiple is the new normal — not a discount.

Web Research — Supreme PLC (SUP)

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Bottom Line from the Web

The single biggest signal the internet provides — well beyond any FY25 filing — is Supreme's 20 April 2026 trading update, in which the Group flagged FY26 revenue of c.$360m and Adjusted EBITDA of c.$55m, significantly ahead of the consensus $333m / $50m. Vape sales rose more than 10% year-on-year even after the disposable ban took effect on 1 June 2025, contradicting the bear thesis that the $70m FY25 disposable revenue would not migrate. The web also reveals a $26m SlimFast acquisition (Oct 2025), a five-year UK Carabao energy-drink licence (Apr 2026), and a $4.1m insider sell-down by CEO Sandy Chadha at $2.04/share (28 Nov 2025) — the largest individual director deal on record at Supreme.

What Matters Most

1. FY26 trading update beats consensus despite the disposable ban

2. Five-year UK Carabao licence — the biggest energy-drinks signal yet

On 21 April 2026 (one day after the trading update), Supreme announced a UK manufacturing-and-distribution licence for Carabao — the Thai energy-drink brand best known for sponsoring the EFL Cup. The deal sits inside Drinks & Wellness (alongside Typhoo, SlimFast and Perfectly Clear) and gives Supreme direct retailer relationships with Morrisons, Asda and Sainsbury's that it did not previously own in this category. Carabao products will be made at Supreme's UK soft-drinks facility. The UK energy-drinks market is one of the top 10 globally by revenue (Statista). Sources: foodmanufacture.co.uk (23 Apr 2026), fdiforum.net, investing.com (21 Apr 2026).

3. SlimFast acquired for $26m — pivots into UK weight-management

On 20 October 2025 Supreme bought SlimFast UK & Europe from Glanbia plc for $26m. TipRanks notes the UK weight-management market is projected to reach $2.0bn by 2027, with the acquisition immediately earnings-enhancing. SlimFast is a recognised brand with existing Boots/Superdrug shelf presence; the IRR depends on Supreme's ability to relaunch into those listings. Sources: thetimes.com, ajbell.co.uk, tipranks.com (20 Oct 2025).

4. CEO Sandy Chadha sold 2.0m shares at $2.04 — $4.1m, "to meet investor demand"

5. UK Vaping Products Duty $2.99/10ml confirmed for 1 October 2026

The web confirms the duty timing and rate (£2.20/10ml; ≈$2.99/10ml at Jan-2026 FX) from multiple primary sources:

• GOV.UK guidance on importing/exporting vaping products references Vaping Products Duty Stamps Scheme.
• BBC reports the £2.20/10ml flat-rate duty confirmed in Reeves' Budget, alongside an equivalent £2.20/100-cigarette tobacco duty rise to maintain the relative incentive to switch.
• A Parliament e-petition (729435) has been raised against the duty by small UK vape businesses — evidence of political contention but no policy reversal.
• Sources: gov.uk, bbc.co.uk/news/articles/cj0j2mj763do, petition.parliament.uk/petitions/729435.

6. Tobacco and Vapes Act 2026 — secondary legislation on flavours/packaging

The Tobacco and Vapes Act 2026 received Royal Assent on 8 May 2026 (per UK Parliament bills.parliament.uk/bills/3879). The Act provides ministers with powers to regulate vape flavours and packaging by secondary legislation and a generational tobacco ban for those born on or after 1 January 2009. Reuters (22 Apr 2026) confirms ~10% of UK adults (5.5m people) currently vape, with growth flattening since 2024. The next material vape-revenue shock is the timing of the first flavour/packaging consultation.

7. Mikhail Stiskin — 7.14% holder reduced to 3.50% (Cyprus-based individual)

8. Bronte Capital — accumulator into March 2026

Supreme is held by Bronte Capital (David Hempton's Sydney-based fund), which added 12.66% to its position in the six months to 31 March 2026 per the original analyst brief. Bronte does not yet appear to have published a partner letter naming Supreme; brontecapital.com/partners-letters confirms the firm's 3-year investment horizon and value-with-low-correlation mandate. The accumulation by a respected long-only fundamental fund is a positive sponsorship signal.

9. Typhoo Tea — $12.8m bargain purchase out of administration (Dec 2024)

The web confirms the bargain-purchase narrative: Supreme paid $12.8m for Typhoo Tea, which had entered administration the prior week. Independent reporting by The Guardian and Proactive Investors corroborates the price. Supreme has marketed this as "saving the UK's oldest brand of pre-packaged tea". Customers include B&M, Home Bargains, Poundland, Tesco, Sainsbury's and Morrisons — i.e. the same retail accounts Supreme already serviced, supporting the cross-sell logic. Sources: proactiveinvestors.com (2 Dec 2024); supreme.co.uk/news/supreme-plc-purchases-typhoo; investegate.co.uk announcement 8583016.

10. ElfBar / Lost Mary master-distributor deal still anchors the licensed-vape model

Since July 2023 Supreme has been master distributor in the UK for ElfBar and Lost Mary — the leading Chinese-owned disposable brands. The disposable ban changed the product mix the deal carries, but Supreme remains the relationship-owner for non-disposable formats from these brands (e-liquids, pods). The Reuters investigation into "Heaven Gifts" — the parent of Elf Bar — flags the regulatory and brand risk attached to the upstream owner; this is a cross-border channel risk that the audited financials do not surface. Sources: marketscreener.com (5 Jul 2023); ecigator.com; tobaccoreporter.com (7 Jul 2023); reuters.com (6 Dec 2023).

Recent News Timeline

What the Specialists Asked

Governance and People Signals

The web reveals a register that is dominated by Chadha's controlling 54.27%, with the remaining float thinly distributed. The most thesis-relevant signal is the CEO sell-down + Stiskin reduction in late 2025 / early 2026 — together they account for c.$10.5m+ of supply absorbed by other institutions. Bronte's accumulation is on the other side of the trade. SimplyWall.st discloses Chadha's total compensation at $821k (51% salary, 8.4-year tenure, 30% direct ownership in their dataset — which differs from the 54.27% RNS figure, likely because Simply Wall St lags or measures differently).

Industry Context

The web confirms three structural shifts that frame the FY26-FY28 thesis:

1. The vape regulatory chain is fully calendared. Disposable ban (Jun 2025) → Vaping Products Duty (Oct 2026) → secondary-legislation flavour/packaging restrictions (TBC, post-May 2026 Act). Each step compresses the addressable market for traditional disposables but creates pricing-power asymmetry for vertically-integrated players (like Supreme, with c.4.5m bottles/week of UK e-liquid capacity per their own divisional disclosure).

2. Drinks & Wellness is the genuine offset. Two material acquisitions (SlimFast $26m, Clearly Drinks $20m) plus the Carabao licence give Supreme real exposure to two growing UK categories: weight management ($2.0bn by 2027) and energy drinks (top-10 global market). The H1 FY26 +17% revenue print, with $21m of uplift attributed to acquisitions, validates the cross-sell thesis at an early stage.

3. The disposable-ban impact is provably manageable. The 20 April 2026 trading update's vape +10% YoY post-ban is the single most important external data point in this entire research file: the worst-case "permanent demand destruction" variant of the bear thesis is no longer supported by the company's own behaviour, even before audited FY26 numbers land in August 2026.

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Where We Disagree With the Market

The market is debating the wrong binary. Bull, Bear and sell-side coverage have all converged on the 1 October 2026 vape duty as the decisive variable, with the H1 FY27 print in November 2026 as the resolver — but the duty is fully calendared, the rate is set, and the 20 April 2026 trading update has already shown vape revenue can grow 10% through a $70m disposable runoff. The genuinely undated, undisclosed, single-RNS binary is whether Heaven Gifts (the Chinese parent of ElfBar / Lost Mary) repeats its US "build-a-beachhead-then-go-direct" playbook in the UK on roughly $97m of H1 FY26 vape revenue Supreme distributes but does not own. Two further disagreements compound this: the consensus reading of the 54.27% founder stake as alignment ignores that the same founder rewrote the long-term incentive plan in FY25 into a one-year Adjusted-EBITDA SIP that mechanically rewards each next acquisition; and the implicit segment values inside the 5.0x EV/EBITDA group multiple are inverted — Electricals (~30% UK battery share, exclusive Energizer/JCB licences) is the segment with the cleanest moat, Vaping (56% of revenue) is the segment with rented brand economics. None of these views require a contrarian narrative; they require the market to look at the disagreement ledger one row past the duty.

Variant Perception Scorecard

The variant strength score reflects three real but contained disagreements with the market — material enough to change underwriting, not radical enough to reposition the stock against a clear consensus tape. Consensus is unusually clear here: every public anchor (sell-side, the death cross, the 5.0x multiple, the 20 April trading update reaction) points to the same single binary, which is exactly what creates the asymmetry on the second binary nobody is sizing. Evidence strength sits in the mid-60s because the disintermediation thesis is supported by a documented Reuters playbook and the H1 FY26 deliberate diversification into IVG / Hayati, but the contract terms with Heaven Gifts are not public — so the disagreement is structural, not specific. The first hard resolver is the FY26 final results in early July (cash conversion, segment GM); the H1 FY27 print in late November 2026 is the cleanest test, roughly nine months out.

---

Consensus Map

What the market appears to believe, with the signals that make each belief consensus rather than just one analyst's view.

The cleanest single anchor for "what consensus believes" is the post-20-April-trading-update tape: the FY26 print landed materially ahead (revenue $365m vs $337m consensus, EBITDA $55.9m vs $50.9m), and the multiple stayed at 5.0x EV/EBITDA. That tells you the market re-priced the disposable-ban leg of the discount but kept the duty discount intact — a precise read on what is and is not in the price.

---

The Disagreement Ledger

Three ranked disagreements, each tied to specific evidence that is in the report but not in the price.

Disagreement #1 — the wrong binary. Consensus would say the Oct-2026 duty is the central event because the rate is large ($3.00 per 10ml is roughly half the wholesale price of a refill bottle), the timing is fixed, and pod GM has already shown 200bps of pre-duty compression. We disagree because the duty is priced and dated — the 5.0x multiple already discounts it. What is not priced is the binary loss of the master-distributor relationship that supplies 30% of vape revenue. The market would have to concede that Vape segment EBITDA could halve in a single RNS, not slide gradually across two reporting periods. The cleanest disconfirming signal is a multi-year ElfBar / Lost Mary renewal RNS or, equivalently, Supreme's vape mix migrating decisively toward owned 88Vape and IVG / Hayati so that ElfBar / Lost Mary falls below 20% of vape revenue — both of which would close the variant view.

Disagreement #2 — founder alignment vs. revenue-buying contract. Consensus would say a founder with $140m at risk and a 163x stake-to-pay ratio is structurally aligned with minorities. We disagree because alignment is what the contract says, and the contract was rewritten in FY25 to a one-year Adjusted-EBITDA SIP — a metric that the next acquisition mechanically lifts and that bargain-purchase accounting feeds into. The FY25 underlying number (Adjusted PBT -2% YoY ex Typhoo bargain gain) and the FY25 FCF-after-acquisitions number (-$4.8m) are exactly what you would expect from a contract that pays for revenue rather than for per-share economics. The market would have to concede that the M&A engine is partly a compensation engine — and re-rate quality of earnings down accordingly. The disconfirming signal is a reinstated 3-year LTIP with a TSR component, or three consecutive halves of cash conversion above 90% with no acquisition added to the base.

Disagreement #3 — inverted segment values. Consensus would say Vaping is the multiple-supporting segment because it has the highest gross margin and dominates revenue mix. We disagree because the moat work shows the segment with the most defensible economic position is Electricals: ~30% UK battery share, multi-decade exclusive licence portfolio, and a value-channel distribution density (50,000 retail outlets) that no UK FMCG peer matches. Vaping has higher headline margin but lower defensibility — pod GM compressed pre-duty, ~30% of revenue is rented from Heaven Gifts, and IMB blu carries the brand equity Supreme's 88Vape does not. The market would have to concede that any segment-multiple rerating story is anchored on the wrong segment, which makes the bull case dependent on Drinks & Wellness margin convergence rather than on vape pod GM. The disconfirming signal is Electricals revenue continuing to decline at -6%/year (the trend) without licence-renewal news — at which point the moat assertion fails on volume even if it holds on share.

---

Evidence That Changes the Odds

The eight pieces of evidence on this page that move the probability of the variant view, isolated from the headline narrative.

The eight items above are the evidence base for the variant view. None of them is exclusive to this analysis — every line is in an upstream tab. What changes when you read them as a set is which binary deserves the highest weight: the duty (consensus), the disintermediation (variant #1), the contract structure (variant #2), or the segment-mix inversion (variant #3).

---

How This Gets Resolved

The signals that close the disagreement, with the document or tape where each one will appear.

The resolution path is dense for a six-month window. Two binaries (vape duty pass-through and ElfBar disintermediation) have observable single-RNS resolvers; two structural views (contract-structure / quality-of-earnings, and segment-mix inversion) resolve gradually across the FY26 final, AGM and FY27 H1 prints. The sequence to watch is: FY26 finals (early July) → AGM remuneration vote and any bolt-on RNS (Aug-Sep) → 1 October 2026 duty effective → 25 November 2026 H1 FY27 print.

---

What Would Make Us Wrong

The strongest argument against variant view #1 — that the market has under-priced Heaven Gifts disintermediation — is that Supreme's H1 FY26 deliberate diversification into IVG and Hayati already shows management hedging the exact risk we are flagging. If the company is replacing the rented brand portfolio with new third-party brands at comparable wholesale margin and similar consumer pull, the binary loss event becomes a slow share rotation across reporting periods, not a single-RNS shock. In that scenario, our disagreement collapses into the consensus duty debate, and the 5.0x multiple is correctly priced because the binary we identified does not exist as a binary. The cleanest test is whether IVG and Hayati combined revenue can replace ElfBar / Lost Mary at sub-1.5x wholesale margin compression — which the FY26 final segment disclosure (early July) will give an early read on.

The strongest argument against variant view #2 — that founder alignment is being mis-read because the contract structure rewards revenue-buying — is the absolute size of the founder's stake. $140m at risk against $421k of base salary is alignment of an order most public companies do not have, and the dollar value of the bonus distortion (a few hundred thousand dollars per year) is trivial relative to the per-share value at risk in any equity raise or governance failure. If Sandy Chadha continues to hold above 50% and refuses to dilute through any acquisition between now and FY28, the contract structure is a second-order issue and the alignment narrative survives. The disconfirming signal here is straightforward: any further insider sale above the $4.1m November 2025 print, or a placing to fund a deal, would close the variant view in our favour; absence of either over the next 12 months would close it against us.

The strongest argument against variant view #3 — that segment values are inverted — is that Electricals' moat is being earned at a -6%/year revenue decline, and a moat on shrinking volume is a compromise asset, not a defensible one. A high-multiple rerating thesis genuinely should anchor on the largest revenue pool (Vaping) because that is where the dollar EBITDA sits. The segment-inversion view depends on Electricals stabilising, which it has not yet done; if FY27 prints another mid-single-digit Electricals decline, the market is correct to discount it as a melting cash floor and our segment-value attribution view is wrong on volume even if it is right on share-of-channel.

The honest red-team summary is that all three variant views are about risk weighting, not about thesis direction. We agree with the bull case that Supreme is high-quality, capital-efficient and trades at a discount that the operating evidence does not justify. We disagree on which binaries the discount is paying for — and on whether the founder-alignment narrative survives a careful read of the FY25 incentive change. None of these views imply that the stock is mispriced in the sense of "buy more"; they imply that the resolution map a PM actually monitors should be wider than the duty.

The first thing to watch is the H1 FY27 vape segment commentary in late November 2026 — not for the gross-margin number consensus is already focused on, but for the disclosed brand-mix breakdown that will tell you whether ElfBar / Lost Mary has been deliberately rotated below 20% of vape revenue. That single disclosure resolves variant view #1 in either direction more cleanly than any duty pass-through datapoint.

Liquidity & Technical

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, technical indicators, and multiples are unitless and unchanged.

Thin trading makes Supreme an execution-constrained name: average daily turnover of about $249K means that even a 0.5% issuer-level position takes roughly five trading weeks to unwind at a 20% participation rate. The tape itself is constructive in the very near term — a sharp +31% one-month rebound has dragged price marginally back above the 200-day average — but a death cross from late November 2025 remains the dominant overhead signal and RSI at 73 says the bounce is already extended.

1. Portfolio implementation verdict

2. Price snapshot

Beta is unavailable for this AIM small-cap; the EWU benchmark series in relative_performance.json is empty for this run, so an explicit beta calculation is omitted rather than fabricated.

3. The critical chart — five years of price with 50/200 SMA

Price is above the 200-day SMA by 1.1% — but only just, and the 50-day average sits roughly $0.24 beneath the 200-day. The five-year regime is best characterised as a deep round-trip: a 2021 IPO-era spike to $3.34, a 2022–2023 collapse to $0.99, a 2024 recovery rally toward $2.70, and a sharp late-2025 drawdown that has been partially reclaimed in the last month. Net regime: range-bound with a bearish moving-average structure that the recent bounce has not yet repaired.

4. Relative strength

5. Momentum panel — RSI + MACD

RSI sits at 73, the highest reading in the last 18 months and well into overbought territory; the MACD histogram (currently +0.58) is positive but compressing for the third consecutive week. Translation: the +31% one-month spike is real but already telegraphing a near-term consolidation. Momentum is bullish on signal direction, stretched on extension — buyers are paying up into resistance, not bottoming on weakness.

6. Volume, volatility and sponsorship

Top three volume spikes (since IPO):

30-day realised volatility is 36% — sitting between the historical 20th percentile (28%) and the median (38%). For an FMCG name the absolute level is high, but it is calm by Supreme's own history, where the 80th percentile sits at 52%. The big volume spikes — including the most recent in late November 2025 — line up with directional moves on no clearly tagged news, suggesting the float is dominated by a handful of holders whose flows show up as event-day liquidations rather than steady institutional sponsorship.

7. Institutional liquidity

A. ADV and turnover

B. Fund-capacity table — what fund AUM does this stock support at typical position weights?

C. Liquidation runway — days to fully exit hypothetical issuer-level positions

D. Intraday range proxy. Median 60-day daily range is 0.9% — tight by AIM standards, suggesting bid-ask cost is not the binding friction; share count is.

Verdict. No size tier clears the five-day threshold without breaching the 20% ADV cap — even the smallest position considered (0.5% of market cap, ~$1.33M) requires roughly five weeks to unwind. The largest positions an institutional account should realistically build are in the $130–270K range over multiple weeks of patient accumulation, equivalent to a 1–2% weight only for funds well under $14M. Above that scale, this is a name to follow, not own.

8. Technical scorecard and stance

Stance: NEUTRAL with a bearish skew on the 3-to-6 month horizon. Net technical score is +1: the bounce is the only positive feature on the page, and it is already at RSI 73 with the death cross structurally intact. The two levels that matter:

• Above $2.38 — clears the 200-day SMA ($2.19) decisively, matches the upper Bollinger Band ($2.39), and would put price ahead of the 50d/200d crossover required to unwind the November death cross. A reclaim of $2.38 flips the stance to constructive.
• Below $1.93 — gives back the 50-day average ($1.95) and confirms the late-2025 selloff is resuming. A break below $1.93 would put a retest of the $1.69 52-week low on the table.

Liquidity is the constraint. Even if the chart were unambiguously bullish, this is not a name that an institutional fund can simply add at a 2% weight on a Tuesday morning — it is a watchlist name to be built slowly across multiple weeks, or a specialist position for sub-$14M small-cap mandates. The technical setup does not yet justify breaking the patience required by the float.